Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma operates with a negative equity position of CNY -53.03 million and a debt-to-equity ratio of -2.41, indicating a leveraged capital structure with liabilities exceeding assets. The company holds CNY 100.07 million in cash and equivalents, but this is offset by CNY 127.76 million in long-term debt, resulting in a net cash position of CNY -27.69 million. The current ratio of 0.66 suggests liquidity constraints, as current liabilities exceed current assets. Profitability metrics show a return on equity of 1.5978 and a return on assets of -0.4842, indicating weak asset utilization and a negative return on invested capital. The company reported a net loss of CNY 84.73 million and an operating loss of CNY 79.78 million, with a gross profit of CNY 10.74 million. These figures fall below the industry median for biotechnology firms, which typically report positive operating margins and higher asset returns. The company's revenue is concentrated in its core bispecific antibody pipeline, with no disclosed geographic diversification. All revenue is generated from its anti-tumor therapies, and no material revenue is attributed to age-related eye disease treatments. The lack of segment reporting limits visibility into geographic or therapeutic diversification. Outlook for the current fiscal year shows a revenue growth of 0% year-over-year, with no improvement in operating income expected. The company is projected to maintain a negative net income, with a free cash flow deficit of CNY 81.22 million. These trends are consistent with the company's early-stage development focus and high R&D expenditures. Risk factors include a medium liquidity risk due to negative net cash and a current ratio below 1. The company has a low dilution risk, with no near-term pressure for equity issuance. However, the risk assessment flags a negative net cash position as a key concern, which could limit operational flexibility. Recent events include the continued development of M701 and the initiation of clinical trials for Y101D and Y332. No material regulatory or legal events were disclosed in the latest filings, and no significant changes in management or strategic direction were reported.